Tag: Cancer: Stomach
ASCO: Pembrolizumab Noninferior to Chemo in Advanced Gastric Cancer
For patients with PD-L1 combined positive score of ≥10, pembrolizumab prolongs overall survival
Pembrolizumab Not Better Than PTX for Advanced Gastric Cancer
Survival no better with second-line pembrolizumab than paclitaxel for gastric, gastro-esophageal cancer
H. Pylori Treatment Tied to Lower Metachronous Gastric Cancer Risk
Those treated after early CA also had improvement in atrophy grade at gastric corpus lesser curvature
Disparities Seen in Gastric Cancer Patients’ Receipt of Pre-Op Chemo
Racial, ethnic disparities in treatment also affect disparities in overall survival
FDA Approves Biosimilar Ogivri for Breast, Stomach Cancers
Ogivri is approved to treat HER2+ breast and gastric or gastroesophageal junction adenocarcinoma cancers
PPI-Gastric Cancer Link Remains After H. Pylori Eradication
Increased risk seen in H. pylori-infected subjects who received eradication therapy
Gastric Cancer Incidence Down, Survival Up
Incidence declined between 1984 and 2014, but long-term survival rates are still low
Ramucirumab Shows Promise in Care of Advanced Gastric Cancer
In two separate trials, hazard ratios for overall survival favor treatment with ramucirumab
Upper Abdominal Cancer Resections Up in Octogenarians
Increase in resection rates driven by trends in hepatic and pancreatic resections
Reconstruction Method in Gastric CA Surgery Affects Bone Density
Billroth-I reconstruction better than Roux-en-Y for preventing bone mineral density loss
